There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Guardant Health (GH – Research Report) and iSpecimen (ISPC – Research Report) with bullish sentiments.
Guardant Health (GH)
Craig-Hallum analyst Alexander Nowak maintained a Buy rating on Guardant Health today. The company’s shares closed last Wednesday at $36.35.
According to TipRanks.com, Nowak is a 3-star analyst with an average return of
Guardant Health has an analyst consensus of Moderate Buy, with a price target consensus of $49.00, representing a 38.8% upside. In a report issued on July 4, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $65.00 price target.
See the top stocks recommended by analysts >>
iSpecimen (ISPC)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on iSpecimen today. The company’s shares closed last Wednesday at $1.33, close to its 52-week low of $1.17.
According to TipRanks.com, Hewitt is a 4-star analyst with an average return of
iSpecimen has an analyst consensus of Moderate Buy.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GH:
